These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28504276)

  • 1. Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment.
    Kim KD; Bae S; Capece T; Nedelkovska H; de Rubio RG; Smrcka AV; Jun CD; Jung W; Park B; Kim TI; Kim M
    Nat Commun; 2017 May; 8():15365. PubMed ID: 28504276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
    Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
    Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
    Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
    Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
    Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of murine tumour growth through CD8
    Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
    Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
    Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
    Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
    Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
    Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
    Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation.
    Krause M; Schmitz M; Noessner E; Skrablin PS; Wehner R; Rieber EP; Baumann M
    Int J Radiat Biol; 2007; 83(11-12):827-36. PubMed ID: 17852560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the in vivo persistence, distribution and function of cytotoxic T lymphocytes by inhibiting the tumor immunosuppressive microenvironment.
    Xu W; Cai J; Li S; Zhang H; Han J; Wen M; Wen J; Gao F
    Scand J Immunol; 2013 Jul; 78(1):50-60. PubMed ID: 23659474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting.
    Takeda K; Nakayama M; Hayakawa Y; Kojima Y; Ikeda H; Imai N; Ogasawara K; Okumura K; Thomas DM; Smyth MJ
    Nat Commun; 2017 Feb; 8():14607. PubMed ID: 28233863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.
    Zimmerman M; Yang D; Hu X; Liu F; Singh N; Browning D; Ganapathy V; Chandler P; Choubey D; Abrams SI; Liu K
    PLoS One; 2010 Nov; 5(11):e14076. PubMed ID: 21124930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    Kemp RA; Ronchese F
    J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective anti-tumor adoptive immunotherapy: utilization of exogenous IL-2-independent cytotoxic T lymphocyte clones.
    Iwashiro M; Jinyan W; Toda M; Linan W; Kato T; Kuribayashi K
    Int Immunol; 2002 Dec; 14(12):1459-68. PubMed ID: 12456594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response.
    Nishikawa H; Kato T; Tawara I; Ikeda H; Kuribayashi K; Allen PM; Schreiber RD; Old LJ; Shiku H
    J Immunol; 2005 Oct; 175(7):4433-40. PubMed ID: 16177085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
    Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S
    Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.